20 August 2026

Moderna Merck Melanoma Vaccine Shows Late-Stage Success

A Moderna-Merck melanoma vaccine reduces recurrence and spread in a late-stage trial, boosting hopes for mRNA cancer treatments.

This article is for Health Matters subscribers

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

Subscribe Log in

Biotechnology, Cancer Immunotherapy, Keytruda, Melanoma, Merck, Moderna, mRNA Cancer Vaccine, Oncology, Personalised Medicine

More from Health Matters

8 October 2026

Cancer in South Africa: Deaths Set to Nearly Double by 2050

Cancer in South Africa is rising, with deaths forecast to nearly double by 2050. Learn what ageing, smoking and urbanisation mean for care.

8 October 2026

Infection Prevention and Control Spending Rises in SA

Hospitals are investing in infection prevention and control as antimicrobial resistance rises, but experts say gaps remain.

8 October 2026

Medicine Shortages: Experts Call for Patient-Access Measures

Experts say South Africa should track medicine shortages by whether patients get full treatment on time, not by stock figures alone.